Your browser doesn't support javascript.
loading
Case Studies for Overcoming Challenges in Using Big Data in Cancer.
Sweeney, Shawn M; Hamadeh, Hisham K; Abrams, Natalie; Adam, Stacey J; Brenner, Sara; Connors, Dana E; Davis, Gerard J; Fiore, Louis D; Gawel, Susan H; Grossman, Robert L; Hanlon, Sean E; Hsu, Karl; Kelloff, Gary J; Kirsch, Ilan R; Louv, Bill; McGraw, Deven; Meng, Frank; Milgram, Daniel; Miller, Robert S; Morgan, Emily; Mukundan, Lata; O'Brien, Thomas; Robbins, Paul; Rubin, Eric H; Rubinstein, Wendy S; Salmi, Liz; Schaller, Teilo H; Shi, George; Sigman, Caroline C; Srivastava, Sudhir.
Afiliación
  • Sweeney SM; American Association for Cancer Research, Philadelphia, Pennsylvania.
  • Hamadeh HK; Genmab, Princeton, New Jersey.
  • Abrams N; Division of Cancer Prevention, Early Detection Research Network, National Cancer Institute, Rockville, Maryland.
  • Adam SJ; Foundation for the National Institutes of Health, Bethesda, Maryland.
  • Brenner S; Office of In Vitro Diagnostics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Connors DE; Foundation for the National Institutes of Health, Bethesda, Maryland.
  • Davis GJ; Abbott Diagnostics Division, Abbott Laboratories, Lake Forest, Illinois.
  • Fiore LD; Boston University School of Medicine, Boston and New England Department of Veterans Affairs, Bedford, Massachusetts.
  • Gawel SH; Abbott Diagnostics Division, Abbott Laboratories, Lake Forest, Illinois.
  • Grossman RL; Center for Translational Data Science, The University of Chicago, Chicago, Illinois.
  • Hanlon SE; Center for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland.
  • Hsu K; Sanofi, Bridgewater, New Jersey.
  • Kelloff GJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
  • Kirsch IR; Adaptive Biotechnologies, Seattle, Washington.
  • Louv B; Project Data Sphere, Morrisville, North Carolina.
  • McGraw D; Ciitizen Platform at Invitae, San Francisco, California.
  • Meng F; Boston University and Veterans Administration Boston Healthcare System, Boston, Massachusetts.
  • Milgram D; CCS Associates, San Jose, California.
  • Miller RS; CancerLinQ, American Society of Clinical Oncology, Alexandria, Virginia.
  • Morgan E; Foundation for the National Institutes of Health, Bethesda, Maryland.
  • Mukundan L; CCS Associates, San Jose, California.
  • O'Brien T; Pfizer, Brooklyn, New York.
  • Robbins P; Pfizer, Brooklyn, New York.
  • Rubin EH; Merck, New York, New York.
  • Rubinstein WS; Office of In Vitro Diagnostics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Salmi L; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Schaller TH; Project Data Sphere, Morrisville, North Carolina.
  • Shi G; Abbott Diagnostics Division, Abbott Laboratories, Lake Forest, Illinois.
  • Sigman CC; Boston University and Veterans Administration Boston Healthcare System, Boston, Massachusetts.
  • Srivastava S; Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland.
Cancer Res ; 83(8): 1183-1190, 2023 04 14.
Article en En | MEDLINE | ID: mdl-36625851
ABSTRACT
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating, and making these data readily accessible to the research community. This review presents five case studies illustrating various successful approaches to addressing such challenges. These efforts are CancerLinQ, the American Association for Cancer Research Project GENIE, Project Data Sphere, the National Cancer Institute Genomic Data Commons, and the Veterans Health Administration Clinical Data Initiative. Critical factors in the development of these systems include attention to the use of robust pipelines for data aggregation, common data models, data deidentification to enable multiple uses, integration of data collection into physician workflows, terminology standardization and attention to interoperability, extensive quality assurance and quality control activity, incorporation of multiple data types, and understanding how data resources can be best applied. By describing some of the emerging resources, we hope to inspire consideration of the secondary use of such data at the earliest possible step to ensure the proper sharing of data in order to generate insights that advance the understanding and the treatment of cancer.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Macrodatos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Cancer Res Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Macrodatos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Cancer Res Año: 2023 Tipo del documento: Article